QT
STML

Quantbot Technologies’s Stemline Therapeutics, Inc. STML Stock Holding History

Quantbot Technologies’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,600
Closed -$32K – 1475
2014
Q1 		$32K Buy
+1,600
New +$38.8K 0.01% 890

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

Quantbot Technologies's STML Position: Q2 2014 in Review

Quantbot Technologies sold out of Stemline Therapeutics, Inc. (STML) in Q2 2014, closing a stake of 1,600 shares — an estimated $32K sold.

Quantbot Technologies first reported a position in STML in Q1 2014 and held it in 1 quarter. The position peaked at $32K in Q1 2014. 61 funds tracked by Wall St. Rank hold STML as of Q2 2014.

  • Quantbot Technologies reported no remaining Stemline Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Quantbot Technologies sold 1,600 Stemline Therapeutics, Inc. shares in Q2 2014, an estimated $32K.
  • Quantbot Technologies first reported a position in Stemline Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Quantbot Technologies's Stemline Therapeutics, Inc. position peaked at $32K in Q1 2014.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2014.

Based on Quantbot Technologies's 13F filing for Q2 2014, filed 8 Jul 2014.